申请人:Aurigene Discovery Technologies Limited
公开号:US09062075B2
公开(公告)日:2015-06-23
The present invention relates to tetrahydropyridine derivatives of formula (1) which may be therapeutically useful as anti-bacterial agents, more particularly FabI inhibitors.
in which X, Y, Z and “n” have the same meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting Enoyl-ACP reductase enzyme (FabI) activity.
The present invention also provides methods for synthesizing and administering the FabI inhibitory compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitory compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
本发明涉及公式(1)的四氢吡啶衍生物,可作为抗菌剂在治疗和预防疾病或紊乱中具有治疗作用,特别是作为FabI抑制剂。其中X、Y、Z和“n”在规范中给出的含义相同,并且具有在抑制Enoyl-ACP还原酶酶(FabI)活性方面具有优势的疾病或紊乱的治疗用途。本发明还提供了合成和给予FabI抑制剂化合物的方法。本发明还提供了包含至少一种FabI抑制剂化合物和其药学上可接受的载体、稀释剂或辅料的制药配方。